JAK1 and metabolic syndrome: Dysfunction in the JAK–STAT signaling pathway has been implicated in the pathogenesis of various metabolic diseases, including metabolic syndrome and diabetes (32), and the JAK1/2 inhibitor baricitinib was shown to preserve β-cell function in a phase 2 clinical trial for stage 3 diabetes (32).